Search results
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC News via Yahoo News· 2 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
The Motley Fool via AOL· 4 days agoAstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company...
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
Bloomberg· 21 hours agoAstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two...
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Benzinga via AOL· 6 days agoOn Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 1 day agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 23 hours agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
The Motley Fool via AOL· 5 days agoAs two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca...
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 1 day agoThe trial results are a step forward for antibody-drug conjugates, which Enhertu makers AstraZeneca...
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks via Yahoo Finance· 5 days agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
The Motley Fool via AOL· 5 days agoAstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more ...